Latest abdominal pain Stories

Great Taste No Pain is the latest program created by Sherry Brescia, who promises to give people an IBS diet plan to help them treat the digestive problem effectively. A full Great Taste No Pain review from the site HealthReviewCenter.com shows if the program is helpful for users to use. Seattle, WA (PRWEB) March 11, 2013 Great Taste No Pain is the newest achievement of Sherry Brescia, who claims to give people the IBS diet plan to help them eliminate the problem of irritable bowel...

OSAKA, Japan, March 7, 2013 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") today announced that a Marketing Authorisation Application (MAA) has been submitted to The European Medicines Agency (EMA) for vedolizumab, an investigational, gut-selective humanized monoclonal antibody for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD), the two most common types of inflammatory bowel disease (IBD). If...

Data Demonstrate Increased Blood Flow and Vasculogenesis in Models of Ischemic Stroke and Peripheral Vascular Disease CAMBRIDGE, Mass., March 5, 2013 /PRNewswire/ -- Tarix Pharmaceuticals, a biopharmaceutical company focused on developing novel, peptide-based therapies to treat a range of critical medical conditions, today announced it has uncovered a new role for its therapeutic peptides in stimulating revascularization following ischemia. In models of ischemic stroke and...

This study is a Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of a new drug in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome (IBS). Orlando, FL (PRWEB) February 28, 2013 Avail Clinical Research is now enrolling for an Irritable Bowel Syndrome Clinical Trial in Florida. To get started, visit Avail Clinical Research or call us directly at (386) 310-1334. Irritable bowel syndrome (IBS) is a...

Research is the first to shed light on how harmful gut bacteria thrive in the intestine Scientists have long puzzled over why “bad” bacteria such as E. coli can thrive in the guts of those with inflammatory bowel disease (IBD), causing serious diarrhea. Now UC Davis researchers have discovered the answer—one that may be the first step toward finding new and better treatments for IBD. The researchers discovered a biological mechanism by which harmful bacteria grow, edge out...

MOUNTAIN VIEW, Calif., Feb. 5, 2013 /PRNewswire/ -- Inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) represent two families of bowel disorders with a common denominator of significant unmet medical need. The main unmet need in IBD is disease modifying therapies with greater efficacy in order to slow disease progression and maintain remission, particularly for severe patients. The development pipeline is bursting with potential candidates to treat IBD. In...

Patients are currently being enrolled in the first clinical trial to investigate the efficacy of immunological therapy for chronic pulmonary sarcoidosis. The trial is being conducted by researchers at the Icahn School of Medicine at Mount Sinai. Mount Sinai has the largest Sarcoidosis Service in the world and is one of only two institutions in the country participating in the trial; the other is the University of Cincinnati. Mount Sinai is a National Institutes of Health Center of...

NEW YORK, Jan. 30, 2013 /PRNewswire-iReach/ -- Having struggled with Crohn's Disease since the early 90's, Warren Sulmasy joined the Crohn's and Colitis Foundation of America (CCFA) in January 2013 to help find a cure for those who struggle with the chronic diseases. In the early 90's, Sulmasy's health began to deteriorate over a period of several months. He lost, 50 pounds and was constantly fatigued. He endured rounds of tests and medication from 12 different doctors until he was...

YORK, England, January 28, 2013 /PRNewswire/ -- Irritable Bowel [http://www.yorktest.com/allergy-or-intolerance/Symptoms-Of-Food-Intolerance/irritable-bowel-syndrome ] Syndrome (IBS) is now one of the most common problems of the digestive system and about one in six people have symptoms. Most people's symptoms are mild and so they may not see a doctor for treatment. However, some people have really troublesome symptoms which seriously impact their quality of life. The most...

NEW YORK and BETHESDA, Md., Jan. 8, 2013 /PRNewswire/ -- TNI BioTech, Inc. (PINKSHEETS: TNIB) announced today that it has signed an agreement for the acquisition of patent rights and orphan drug designation by the FDA to a novel late-stage drug, trademarked "LDN," for the treatment of Pediatric Crohn's Disease. TNI BioTech has signed a licensing agreement to acquire the exclusive patent rights for the intellectual property of Dr. Jill Smith and LDN Research LLC,...